Penn Medicine expanded across the Atlantic into the United Kingdom after the launch of the Penn Medicine London center last month.
The center, which opened on Nov. 19, will allow patients from the United Kingdom and across the European Union to access Penn Med's health experts through referrals and telemedicine service. It will also allow Penn to work closely with medical schools in the United Kingdom.
“Penn Medicine has a long history – dating past the founding of our nation – as a global healthcare leader, and we are pleased to extend our reach with a physical presence in the U.K.,” Ralph Muller, Chief Executive Officer of Penn Med, said in a Nov. 19 press release. “We have always been proud of our role in training the world, and this initiative advances that mission by opening new doors and forging new relationships both in the U.K. and across Europe."
Penn Med has also had a global impact and previously partnered with European institutions.
In 2017, the U.S. Food and Drug Administration approved a gene-altering cancer treatment that Penn Medicine designed. This chimeric antigen receptor T-cell (CAR T) treatment was then approved by the European Commission and has been successfully used to treat blood cancer across the globe. Switzerland-based pharmaceutical company Novartis also partnered with Penn Med to conduct the research.
Penn Med has also collaborated with U.K. institutions, including a study that contradicted past findings about some health benefits of alcohol that was conducted with University College London and the London School of Hygiene & Tropical Medicine.
Penn Med also holds an affiliation with King’s College London GKT School of Medical Education, where each school offers its final-year medical students clinical elective placements at the partner school.